NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$381.17 +2.66 (+0.70 %)
(As of 12/16/2018 04:00 PM ET)
Previous Close$381.17
Today's Range$379.00 - $386.90
52-Week Range$281.89 - $416.49
Volume728,960 shs
Average Volume630,735 shs
Market Capitalization$41.25 billion
P/E Ratio28.42
Dividend YieldN/A
Beta1.36
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:REGN
Previous Symbol
CUSIP75886F10
Phone914-847-7000

Debt

Debt-to-Equity Ratio0.09
Current Ratio4.04
Quick Ratio3.30

Price-To-Earnings

Trailing P/E Ratio28.42
Forward P/E Ratio20.19
P/E Growth1.68

Sales & Book Value

Annual Sales$5.87 billion
Price / Sales7.02
Cash Flow$15.8623 per share
Price / Cash Flow24.03
Book Value$57.09 per share
Price / Book6.68

Profitability

EPS (Most Recent Fiscal Year)$13.41
Net Income$1.20 billion
Net Margins28.24%
Return on Equity30.24%
Return on Assets21.59%

Miscellaneous

Employees6,200
Outstanding Shares108,210,000
Market Cap$41.25 billion
OptionableOptionable

Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) issued its quarterly earnings data on Tuesday, November, 6th. The biopharmaceutical company reported $5.87 earnings per share for the quarter, beating the consensus estimate of $4.94 by $0.93. The biopharmaceutical company had revenue of $1.66 billion for the quarter, compared to analysts' expectations of $1.64 billion. Regeneron Pharmaceuticals had a return on equity of 30.24% and a net margin of 28.24%. The business's revenue was up 10.8% on a year-over-year basis. During the same period last year, the business earned $3.99 EPS. View Regeneron Pharmaceuticals' Earnings History.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Regeneron Pharmaceuticals.

What price target have analysts set for REGN?

22 brokerages have issued 1-year price targets for Regeneron Pharmaceuticals' shares. Their forecasts range from $305.00 to $530.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $408.3889 in the next year. This suggests a possible upside of 7.1% from the stock's current price. View Analyst Price Targets for Regeneron Pharmaceuticals.

What is the consensus analysts' recommendation for Regeneron Pharmaceuticals?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 15 hold ratings, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Regeneron Pharmaceuticals.

What are Wall Street analysts saying about Regeneron Pharmaceuticals stock?

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:
  • 1. JPMorgan Chase & Co. analysts commented, "REGN today reported in-line 3Q product sales (total rev +$21M; 1%) and a bottom-line beat (+$0.74; 14%) while tightening and lowering OpEx/tax guidance. The 3Q print/call was rather uneventful albeit high on details; Eylea was generally in line with expectations (+7% YoY), and Dupixent/Praluent/Kevzara numbers were known following SNY’s print last Wednesday. With many (not all) 4Q18 clinical/regulatory catalysts in the rear view mirror, we expect investors to focus on ongoing product launches and the robustness of the Eylea franchise. Maintain Neutral." (11/7/2018)
  • 2. According to Zacks Investment Research, "The performance of Regeneron's key growth driver, Eylea, is impressive and the potential label expansion of Eylea in patients with wet age-related macular degeneration will further boost sales. Meanwhile, Dupixent uptake in the United States for moderate-to-severe atopic dermatitis was encouraging and a label expansion of the drug will further boost sales. However, the company is heavily dependent on Eylea for growth. Investors are cautious as the company had earlier suffered setback when it decided not to advance the nesvacumab and Eylea combination study to phase III development after two phase II studies evaluating the combination therapy failed to show additional benefit over Eylea monotherapy in patients with diabetic macular edema or wet age-related macular degeneration. Any setbacks will adversely hurt the stock. Shares have underperofrmed the industry in the last six months." (7/3/2018)
  • 3. Canaccord Genuity analysts commented, "We are encouraged by better US Dupixent growth, but recognize that the pediatric atopic dermatitis market will be the core growth driver, with approval expected around 2021. Also, while we understand that REGN and investors are focusing more on Dupixent’s growth than EYLEA’s, the lack of EYLEA guidance going forward is concerning. REGN cannot give guidance on Dupixent since Sanofi books the revenues, and EYLEA is still expected to be the core revenue driver for REGN." (2/7/2018)

Has Regeneron Pharmaceuticals been receiving favorable news coverage?

News articles about REGN stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Regeneron Pharmaceuticals earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are some of Regeneron Pharmaceuticals' key competitors?

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the folowing people:
  • Dr. Leonard S. Schleifer, Co-Founder, Pres, CEO & Exec. Director (Age 65)
  • Dr. George D. Yancopoulos, Pres, Chief Scientific Officer & Director (Age 58)
  • Mr. Robert E. Landry Jr., Sr. VP of Fin. & CFO (Age 54)
  • Dr. Neil Stahl, Exec. VP of R&D (Age 61)
  • Mr. Daniel P. Van Plew, Exec. VP and Gen. Mang. of Industrial Operations & Product Supply (Age 45)

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Capital World Investors (5.91%), BlackRock Inc. (5.42%), Vanguard Group Inc. (5.32%), Vanguard Group Inc (5.32%), FMR LLC (4.64%) and Loomis Sayles & Co. L P (3.10%). Company insiders that own Regeneron Pharmaceuticals stock include Charles A Baker, George L Sing, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

Which institutional investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Manning & Napier Group LLC, HealthCor Management L.P., Renaissance Technologies LLC, BlackRock Inc., Canada Pension Plan Investment Board, Mitsubishi UFJ Trust & Banking Corp and BB Biotech AG. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Which institutional investors are buying Regeneron Pharmaceuticals stock?

REGN stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, FMR LLC, Capital World Investors, Alliancebernstein L.P., Ffcm LLC, Morgan Stanley, Candriam Luxembourg S.C.A. and First Trust Advisors LP. View Insider Buying and Selling for Regeneron Pharmaceuticals.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $381.17.

How big of a company is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has a market capitalization of $41.25 billion and generates $5.87 billion in revenue each year. The biopharmaceutical company earns $1.20 billion in net income (profit) each year or $13.41 on an earnings per share basis. Regeneron Pharmaceuticals employs 6,200 workers across the globe.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is http://www.regeneron.com.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]


MarketBeat Community Rating for Regeneron Pharmaceuticals (NASDAQ REGN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  1,210 (Vote Outperform)
Underperform Votes:  963 (Vote Underperform)
Total Votes:  2,173
MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe REGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2018 by MarketBeat.com Staff

Featured Article: NASDAQ

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel